Eli Lilly's Compassionate Use Program Grants Access to Experimental Obesity Drug for 79-Year-Old
In a notable case, Eli Lilly and the FDA have provided a 79-year-old patient with access to an experimental obesity drug through the compassionate use program, highlighting ethical considerations in drug access.
Editorial Staff
1 min read
Updated about 5 hours ago
A 79-year-old patient has received extraordinary access to an experimental obesity drug, thanks to Eli Lilly and the FDA's compassionate use program.
This drug remains in the experimental stages, raising questions about the ethics of providing such access to individuals.
The situation underscores the complex intersection of medical ethics and the availability of innovative treatments for patients in need.